Home › Transthyretin-Related Hereditary Amyloidosis › NCT06465810
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
Who can join
Ages 18 to 130 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patient willing and able to provide written informed consent to participate in the study * Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis * Aged ≥18 years at the time of signing the informed consent * Patient willing and able to participate in collection of electronic patient reported outcomes (PROs) Exclusion Criteria: * Concurrent participation in any interventional trial for ATTR amyloidosis * Involvement in the planning and/or conduct of the current study * Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA) * Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
About the study
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
What is being tested
- Treatment of transthyretin (ATTR) amyloidosis in observational study setting (drug)
Sponsor: AstraZeneca · Participants: 1,850 · Started: Jun 25, 2024
Contact the study team
- AstraZeneca Clinical Study Information Center · Phone: 1-877-240-9479
Official record on ClinicalTrials.gov — NCT06465810
Locations in the U.S.
Conditions
- Transthyretin-Related Hereditary Amyloidosis
- Amyloidosis
- Familial Amyloid Neuropathies
- Polyneuropathies
- Familial Amyloidosis
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.